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Abstract
Singapore is endemic for Dengue virus, with approximately 10,000 to 20,000 annual cases reported in recent years. In
2012, Chikungunya was introduced, although the numbers of cases reported is much fewer. The current Zika virus
pandemic originating in Brazil represents a threat to all regions with Aedes mosquitoes, particularly those well connected
by travellers. In this respect, it was felt inevitable that Singapore would eventually realise its third endemic flavivirus. In late
August 2016, a primary care practitioner observed a cluster of geographically linked patients attending with fever and
rash. This resulted in the first identification of locally transmitted Zika in Singapore on August 27, 2016. This prompted a
robust response in an attempt to stop further spread, which continued for approximately 10 days until a large number of
laboratory-confirmed cases were found as a result of active case finding. Surprisingly, the strain was later identified to be
of Asian lineage and distinct from that originating in the Americas, prompting speculation over the epidemiology of this
under recognised virus in Asia.
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Background
By early October 2016, 73 countries had reported autoch-
thonous transmission of Zika virus (ZIKV) since 2007 [1].
Singapore joined this list on August 27, 2016, and while this
first identified case signalled a large outbreak, the subse-
quent realisation that this outbreak was unrelated to that of
the Americas raises many questions regarding ZIKV
epidemiology in Southeast Asia.
Tracking the epidemiology in countries
Internationally, the identification of ZIKV cases is heavily
influenced by the sophistication of health systems, afford-
able, convenient availability of testing, the health seeking
behaviour of individuals, and the severity of the illness,
together with treatment options. Given that this is gener-
ally a mild (usually asymptomatic) disease with no treat-
ment and which occurs in tropical regions, when dealing
with the inevitable underreporting of ZIKV, international
organisations categorise affected countries to describe
current reports without dismissing past reported cases.
The European Centre for Disease Prevention and Control,
the World Health Organization, and the US Centres for
Disease Control and Prevention have categories to describe
countries with recent or current outbreaks, sporadic or en-
demic disease, or past transmission, and countries at risk
including risk stratification based on the presence of Aedes
mosquitos or Dengue virus (DENV) [1–3]. However, these
strategies largely manage the varied efforts involved in case
finding and testing (both between countries and temporally
within countries). Vector control, personal protective ef-
forts and, to some extent, herd immunity can end an out-
break but will likely lead to a baseline low level endemicity.
Elimination is possible in areas of low population density as
has been the experience with DENV in Australia. However,
where elimination is achieved, vulnerability remains and
reintroduction is the norm [4].
Of the 73 countries hosting ZIKV transmission in the
last decade, 64 have documented cases in the last
9 months and 58 in the last 3 months. It is highly likely,
however, that countries absent from more recent lists
have accepted ongoing transmission but have higher
health priorities precluding substantive ZIKV surveil-
lance. Countries with Aedes mosquitoes generally have
endemic DENV and, in practice, neither can be sustain-
ably eradicated [4, 5].
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The risk of ZIKV introduction to Singapore and the
likelihood of it becoming endemic has been well recognized
locally for some years. Dengue is endemic in Singapore,
with disease predominantly in adults. Recent outbreaks
have resulted in over 10,000 notified cases per year, includ-
ing a peak of 22,170 cases in 2013. This is despite highly
successful vector control programmes legislated since 1966
[6]. This paradoxical outcome is believed to be due to
decreased childhood exposure and therefore a lack of im-
munity in adulthood when exposure is more likely to have
a symptomatic presentation.
Combining this setting, apt for a new mosquito-borne
flavivirus, with Singapore’s global connectedness of
approximately 15 million tourists per year, the issue was
‘when’, rather than ‘if ’, Singapore would join the list of
ZIKV affected countries [7]. However, the expectation was
that it would be the strain originating in the Americas,
which is central to the current international spread.
ZIKV surveillance in Singapore
In an effort to identify the apparently inevitable introduc-
tion, Singapore had undertaken regular routine surveillance
for ZIKV since 2014 after the outbreak in French Polynesia
in 2013 [8]. Samples negative for DENV diagnostic testing
were used for ZIKV surveillance. This surveillance was
scaled up significantly after reports in January 2016 describ-
ing the large ZIKV outbreak in Brazil and its possible
association with microcephaly.
Ministry of Health advisories alerted doctors to test trav-
ellers from ZIKV-affected areas with compatible symptoms.
All blood samples were tested at the National Public Health
Laboratory using RT-PCR. Furthermore, public travel advi-
sories gave information about avoiding ZIKV infection and
also presenting early if symptoms were present on return.
Managing the first cases
In May 2016, a Singapore resident returning from Brazil
became the first (imported) confirmed case prompting
containment efforts. Vector control operations around
his residence were intensified for a week. Doctors were
asked to refer patients with compatible symptoms and
an epidemiological link to the area. The man was iso-
lated in hospital until he was no longer viraemic and no
further cases were detected.
The first case of local transmission of ZIKV was reported
on August 27, 2016, and this time prompted enhanced con-
tainment efforts comprising screening of those living or
working around confirmed cases, referral of suspect cases
to hospitals for ZIKV testing, isolation of viraemic cases,
and intensive vector control. Over 200 positive diagnoses
were made in the first week, including over 50 diagnoses
from retrospective testing of patients with recent symp-
toms. After 2 weeks, over 300 cases had been identified.
Clearly, the ‘first case’ was not the index: other clusters
geographically separate in Singapore were found and con-
tainment involving isolation of cases was discontinued after
10 days. Intensive vector control around clusters of cases
continued, including community engagement to prevent
mosquito breeding.
Going forward, clinical management involving ZIKV
has been prioritized to symptomatic pregnant women,
with testing fully subsidized. A national expert advisory
group has provided guidelines for the clinical manage-
ment of ZIKV infection in pregnancy. Surveillance has
been enhanced via selected primary care clinics and tests
on DENV-negative serum will continue as previously.
Why an outbreak of the Asian lineage now?
It is not clear why this outbreak occurred. The case in
May (a traveller from Brazil) carried the strain that is part
of the world pandemic. However, the August outbreak
strain is a distinctly different Asian lineage circulating
since the 1960s [9].
It is quite possible that ZIKV has been circulating for de-
cades in Asia, and even in Singapore, but the absence of
specific tests for antibodies denies the possibility of a sero-
prevalence study. In fact, the major issue in defining such a
test (or therapeutic) is cross reactivity with other flaviruses,
particularly DENV [10]. Indeed, some of the cases over the
years diagnosed serologically as a DENV infection could
have been ZIKV.
Whether or not there is a baseline low level of ZIKV in
Singapore does not replace the fact that this was an out-
break starting at least some generations prior to August 27;
this may have been a chance occurrence or it may be a re-
sult of ongoing urbanization across Asia, with adaptation
by Aedes species of mosquito and possibly evolution of the
ZIKV genotype, behaving similarly, both virologically and
epidemiologically, to Chikungunya and DENV [11].
Conclusion
In Singapore, more than 1 month after the reporting of
the first confirmed locally acquired case and after the la-
boratory confirmation of over 400 cases, case numbers
have dropped to below 10 per week. The public and the
medical community have accepted the inevitability of the
disease, but because of its mild (usually asymptomatic) na-
ture, understanding what happened and tracking the epi-
demiology of ZIKV will be a challenge. This would be
acceptable if not for the potential impact on the unborn
and occasional neurological sequelae in adults. ZIKV will
likely persist in Singapore and cause occasional outbreaks
and new strains will periodically be introduced. Under-
standing the molecular epidemiology and the clinical im-
pact, establishing specific antibody tests and multiplex
PCRs, and striving for treatments, particularly vaccines, all
form part of the international research agenda [12]. The
current response capacity to counter ZIKV is limited to
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vector control. The targeted knowledge and tools once
available will be a welcome addition to health system
managers and clinicians in the future.
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